JAMA:ICU患者感染事件发生率及临床结局

2020-03-25 MedSci原创 MedSci原创

接受ICU治疗患者疑似或证实感染风险很高,导致住院死亡率增加

重症监护病房(ICU)的病人感染风险较高,近日研究人员就ICU患者感染类型、致病病原体和结果数据进行了考察。
 
研究在88个国家的1150个ICU中心开展,24小时接受ICU治疗的患者参与研究,考察患者感染诊断及抗生素使用数据。研究的主要终点为感染率、抗生素使用率和全因住院死亡率。
 
15202名患者参与研究,平均年龄61.1岁,9181名男性,8135名(54%)已怀疑或证实存在感染,其中1760名(22%)为ICU获得性感染。共有10640名(70%)患者至少接受了1种抗生素治疗。不同地区的感染率存在差异,其中澳大利亚最低为43%,亚洲及中东最高为60%。在8135名疑似或已证实感染的患者中,5259名(65%)至少有1种微生物培养阳性;其中67%的患者(n=3540)发现革兰氏阴性感染,37%的患者(n=1946)发现革兰氏阳性感染,16%的患者发现真菌感染(n=864)。疑似或已证实感染患者住院死亡率为30%(2404/7936)。在多层次分析中,与社区获得性感染相比,ICU获得性感染与更高的死亡风险独立相关(优势比[OR]:1.32)。在抗生素耐药微生物中,万古霉素耐药肠球菌(OR:2.41),对β-内酰胺抗生素耐药的克雷伯菌,包括第三代头孢菌素和碳青霉烯类抗生素(OR:1.29)或耐碳青霉烯类不动杆菌 (OR:1.40)感染患者的死亡风险较高。
 
全球范围内,接受ICU治疗患者疑似或证实感染风险很高,导致住院死亡率增加。
 
原始出处
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826587, encodeId=0974182658ea9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Oct 31 00:54:12 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843215, encodeId=7e1b1843215d6, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jan 05 14:54:12 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033094, encodeId=85a5203309459, content=<a href='/topic/show?id=25325329671' target=_blank style='color:#2F92EE;'>#感染事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53296, encryptionId=25325329671, topicName=感染事件)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Dec 25 15:54:12 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595381, encodeId=c233159538143, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Mar 27 09:54:12 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035985, encodeId=7274103598507, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Mar 25 21:54:12 CST 2020, time=2020-03-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826587, encodeId=0974182658ea9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Oct 31 00:54:12 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843215, encodeId=7e1b1843215d6, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jan 05 14:54:12 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033094, encodeId=85a5203309459, content=<a href='/topic/show?id=25325329671' target=_blank style='color:#2F92EE;'>#感染事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53296, encryptionId=25325329671, topicName=感染事件)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Dec 25 15:54:12 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595381, encodeId=c233159538143, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Mar 27 09:54:12 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035985, encodeId=7274103598507, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Mar 25 21:54:12 CST 2020, time=2020-03-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826587, encodeId=0974182658ea9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Oct 31 00:54:12 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843215, encodeId=7e1b1843215d6, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jan 05 14:54:12 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033094, encodeId=85a5203309459, content=<a href='/topic/show?id=25325329671' target=_blank style='color:#2F92EE;'>#感染事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53296, encryptionId=25325329671, topicName=感染事件)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Dec 25 15:54:12 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595381, encodeId=c233159538143, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Mar 27 09:54:12 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035985, encodeId=7274103598507, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Mar 25 21:54:12 CST 2020, time=2020-03-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1826587, encodeId=0974182658ea9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Oct 31 00:54:12 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843215, encodeId=7e1b1843215d6, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jan 05 14:54:12 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033094, encodeId=85a5203309459, content=<a href='/topic/show?id=25325329671' target=_blank style='color:#2F92EE;'>#感染事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53296, encryptionId=25325329671, topicName=感染事件)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Dec 25 15:54:12 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595381, encodeId=c233159538143, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Mar 27 09:54:12 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035985, encodeId=7274103598507, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Mar 25 21:54:12 CST 2020, time=2020-03-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1826587, encodeId=0974182658ea9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Oct 31 00:54:12 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843215, encodeId=7e1b1843215d6, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jan 05 14:54:12 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033094, encodeId=85a5203309459, content=<a href='/topic/show?id=25325329671' target=_blank style='color:#2F92EE;'>#感染事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53296, encryptionId=25325329671, topicName=感染事件)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Dec 25 15:54:12 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595381, encodeId=c233159538143, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Mar 27 09:54:12 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035985, encodeId=7274103598507, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Mar 25 21:54:12 CST 2020, time=2020-03-25, status=1, ipAttribution=)]
    2020-03-25 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

战疫者|武汉肺科医院ICU主任:连轴转720小时

2月1日,武汉,晴转阴。这座被新型冠状病毒肺炎阴影“笼罩”的城中,最美的身影仍属于奋战在抗疫一线的人们。武汉肺科医院仁医楼十三层的重症监护室(ICU),收治着数十名“危重新型冠状病毒肺炎病人”,他们正接受进一步治疗。记者见到ICU主任胡明时,他正身穿暗绿色短袖工作制服、满头大汗从重症监护室走出来。在此之前,他刚和其他几名教授完成一次ECMO(移动心肺仪)病人的转移,约50米的距离,耗时近40分

JAMA:ICU应激性溃疡预防策略与死亡率——PPI vs H2RB

研究发现,在需要机械通气的ICU患者中,使用质子泵抑制剂或组胺-2受体阻滞剂作为应激性溃疡预防策略导致的医院死亡率无显著性差异。

NEJM:轻度镇静或不镇静对ICU通气患者死亡率的影响

在ICU机械通气患者中,无镇静或每日中断轻度镇静组间90天的死亡率无显著差异

2020 SCCM指南:ICU内成人急性和慢加急性肝衰竭的管理

2020年2月,美国重症医学会(SCCM)发布了ICU内成人急性和慢加急性肝衰竭的管理指南,主要目的是为ICU内成人急性和慢加急性肝衰竭的管理提供循证指导建议。共29条建议涉及五类情况即,心血管、血液、肺脏、肾脏和内分泌。

ICU医生眼里的ICU:与死神抗争,也要尊重人性

在多数人印象中,ICU(重症监护室)既神秘又让人敬畏。里面的患者全身插满管子,监护仪的报警声此起彼伏,炽烈的灯光昼夜长明,不时会有患者因抢救无效死亡。

美国重症医学会“以家庭为中心照护循证指南”解读

推动重症监护室以家庭为中心照护(Family-Centered Care,FCC),增加患者家属的参与度,最终提升患者安全是国际重症医学领域发展目标之一。美国重症医学会招募专家就其实施过程中的临床问题制定了循证指南,旨在帮助重症科室工作人员实施FCC。通过解读指南,帮助医护人员从家属在场、家庭支持、良性沟通、提供专业咨询和构建专业团队、运营和环境管理五个方面深入理解FCC 实施方法,为科室FCC